Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults
- PMID: 17115871
- DOI: 10.1037/1064-1297.14.4.439
Cognitive and subjective acute dose effects of intramuscular ketamine in healthy adults
Abstract
Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) antagonist. Given the purported role of the NMDA receptor in long-term potentiation, the primary purpose of the present study was to further understand the dose-related effects of ketamine on memory. The study was also designed to provide information about the relative effects of ketamine on memory versus nonmemory effects and to more fully characterize ketamine's overall pattern and time course of effects. Single intramuscular injections of ketamine (0.2 mg/kg, 0.4 mg/kg) were administered to 18 healthy adult volunteers using a double-blind, placebo-controlled, crossover design. Word lists were used to evaluate episodic memory (free recall, recognition memory, source memory) and metamemory. Working memory, time estimation, psychomotor performance, and subjective effects were assessed repeatedly for 5 hours after drug administration. Ketamine selectively impaired encoding (as measured by free recall) while sparing retrieval, working memory while sparing attention, and digit symbol substitution task speed while sparing accuracy. Ketamine did not significantly impair recognition or source memory, metamemory, or time estimation. There were no hallucinations or increases in mystical experiences with ketamine. Memory measures were less sensitive to ketamine effects than subjective or psychomotor measures. Subjective effects lasted longer than memory and most psychomotor impairments. Ketamine produces selective, transient, dose- and time-related effects. In conjunction with previous studies of drugs with different mechanisms of actions, the observed selectivity of effects enhances the understanding of the pharmacological mechanisms underlying memory, attention, psychomotor performance, and subjective experience.
Similar articles
-
Effects of sub-anesthetic doses of ketamine on rats' spatial and non-spatial recognition memory.Neuroscience. 2008 Jun 23;154(2):454-60. doi: 10.1016/j.neuroscience.2008.04.001. Epub 2008 Apr 7. Neuroscience. 2008. PMID: 18472348
-
Effects of pharmacologically induced changes in NMDA receptor activity on human timing and sensorimotor performance.Brain Res. 2006 Feb 16;1073-1074:407-16. doi: 10.1016/j.brainres.2005.12.019. Epub 2006 Jan 19. Brain Res. 2006. PMID: 16423331 Clinical Trial.
-
Sedation and memory: studies with a histamine H-1 receptor antagonist.J Psychopharmacol. 2006 Jul;20(4):506-17. doi: 10.1177/0269881106059804. Epub 2006 Jan 9. J Psychopharmacol. 2006. PMID: 16401664 Clinical Trial.
-
Acute and chronic effects of ketamine upon human memory: a review.Psychopharmacology (Berl). 2006 Nov;188(4):408-24. doi: 10.1007/s00213-006-0572-3. Epub 2006 Sep 28. Psychopharmacology (Berl). 2006. PMID: 17006715 Review.
-
[Pharmacological modulation of the effects induced by ketamine at subanesthetic doses].Therapie. 2001 Sep-Oct;56(5):617-22. Therapie. 2001. PMID: 11806303 Review. French.
Cited by
-
Towards an Explanation of Subjective Ketamine Experiences among Young Injection Drug Users.Addict Res Theory. 2008;16(3):273-287. doi: 10.1080/16066350801983749. Addict Res Theory. 2008. PMID: 18941540 Free PMC article.
-
A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.Neuropharmacology. 2018 Nov;142:270-276. doi: 10.1016/j.neuropharm.2018.01.005. Epub 2018 Jan 5. Neuropharmacology. 2018. PMID: 29309770 Free PMC article. Clinical Trial.
-
Therapeutic infusions of ketamine: do the psychoactive effects matter?Drug Alcohol Depend. 2014 Mar 1;136:153-7. doi: 10.1016/j.drugalcdep.2013.12.019. Epub 2014 Jan 15. Drug Alcohol Depend. 2014. PMID: 24480515 Free PMC article. Clinical Trial.
-
Diverse and often opposite behavioural effects of NMDA receptor antagonists in rats: implications for "NMDA antagonist modelling" of schizophrenia.Psychopharmacology (Berl). 2009 Aug;205(2):203-16. doi: 10.1007/s00213-009-1530-7. Epub 2009 May 7. Psychopharmacology (Berl). 2009. PMID: 19421743
-
A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.Psychopharmacology (Berl). 2020 Feb;237(2):317-328. doi: 10.1007/s00213-019-05366-1. Epub 2019 Nov 26. Psychopharmacology (Berl). 2020. PMID: 31773211 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources